Gastrointestinal Neuroendocrine Tumor Clinical Trials

3 recruiting

Gastrointestinal Neuroendocrine Tumor Trials at a Glance

6 actively recruiting trials for gastrointestinal neuroendocrine tumor are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Bethesda, Ann Arbor, and Dallas. Lead sponsors running gastrointestinal neuroendocrine tumor studies include National Cancer Institute (NCI), Aadi Bioscience, Inc., and Arbele Pty Ltd.

Browse gastrointestinal neuroendocrine tumor trials by phase

Treatments under study

About Gastrointestinal Neuroendocrine Tumor Clinical Trials

Looking for clinical trials for Gastrointestinal Neuroendocrine Tumor? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastrointestinal Neuroendocrine Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastrointestinal Neuroendocrine Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 2

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Pancreatic AdenocarcinomaPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center66 enrolled3 locationsNCT05988918
Recruiting
Phase 1Phase 2

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Phase 1

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Liver CancerPancreatic CancerGastric Cancer+6 more
Arbele Pty Ltd68 enrolled3 locationsNCT05411133
Recruiting

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Breast CancerMelanomaGastrointestinal Neuroendocrine Tumor
University Health Network, Toronto500 enrolled1 locationNCT05196087
Recruiting
Phase 2

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Neuroendocrine TumorsPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+2 more
Aadi Bioscience, Inc.21 enrolled4 locationsNCT05997056